BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1151@pharmaconomics
DTSTAMP:20260707T051349Z
DTSTART;VALUE=DATE:20260108
DTEND;VALUE=DATE:20260109
SUMMARY:ASND Phase 2 — TransCon CNP
DESCRIPTION:Phase 2 trial results for TransCon CNP in achondroplasia are due Jan 8\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1612042/000119312526007934/d27768d6k.htm\n\nTrack it: https://www.pharmaconomics.com/e/1151
URL:https://www.pharmaconomics.com/e/1151
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:ASND catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR